| Literature DB >> 24321201 |
Chan Ho Kim, Jung Tak Park, Eun Jin Kim, Jae Hyun Han, Ji Suk Han, Jun Yong Choi, Seung Hyeok Han, Tae-Hyun Yoo, Young Sam Kim, Shin-Wook Kang, Hyung Jung Oh.
Abstract
INTRODUCTION: A potential independent association was recently demonstrated between high red blood cell distribution width (RDW) and the risk of all-cause mortality in critically ill patients, although the mechanism underlying this relationship remains unclear. Little is known about the impact changes in RDW may have on survival in critically ill patients. Therefore, we investigated the prognostic significance of changes in RDW during hospital stay in patients with severe sepsis or septic shock.Entities:
Mesh:
Year: 2013 PMID: 24321201 PMCID: PMC4056357 DOI: 10.1186/cc13145
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flow diagram of study subjects. From November 2001 to November 2011, 436 patients who received early-goal directed therapy (EGDT) in the emergency department (ED) were assessed for possible enrollment according to inclusion and exclusion criteria, and 329 patients were included in the final analysis.
Comparisons of clinical and biochemical variables according to baseline RDW value and ΔRDW
| | | | ||||
|---|---|---|---|---|---|---|
| Age (years) | 64.4 ± 15.6 | 59.7 ± 17.9 | 67.0 ± 12.1 | 66.3 ± 14.3 | 67.2 ± 15.7 | 0.002 |
| Male, n (%) | 161 (48.9%) | 47 (43.5%) | 36 (57.1%) | 56 (46.3%) | 22 (59.5%) | 0.176 |
| MAP (mmHg) | 60.0 ± 8.3 | 60.2 ± 8.7 | 60.7 ± 7.7 | 59.7 ± 7.9 | 59.4 ± 9.8 | 0.863 |
| BMI (kg/m2) | 23.0 ± 3.9 | 23.3 ± 4.1 | 22.1 ± 4.4 | 23.3 ± 3.4 | 22.7 ± 3.9 | 0.150 |
| APACHE II score | 17.5 ± 7.3 | 14.8 ± 6.4 | 19.2 ± 17.3 | 17.3 ± 6.7 | 23.0 ± 7.6 | <0.001 |
| SOFA score | 8.1 ± 2.8 | 7.0 ± 2.5 | 8.8 ± 2.7 | 8.1 ± 2.9 | 9.5 ± 3.0 | <0.001 |
| Charlson Comorbidity Index | 1.4 ± 1.5 | 1.1 ± 1.3 | 2.0 ± 1.7 | 1.2 ± 1.4 | 1.5 ± 1.5 | 0.001 |
| RDW at baseline (%) | 14.0 ± 1.6 | 13.2 ± 0.7 | 16.0 ± 1.3 | 13.0 ± 0.8 | 15.8 ± 1.1 | <0.001 |
| RDW at 72 hours (%) | 14.1 ± 1.6 | 13.0 ± 0.7 | 15.6 ± 1.3 | 13.6 ± 0.8 | 16.5 ± 1.2 | <0.001 |
| WBC (x 103/mm3) | 13.9 ± 9.3 | 13.0 ± 7.4 | 15.1 ± 12.0 | 14.5 ± 9.8 | 12.2 ± 6.2 | 0.286 |
| Hemoglobin (g/dL) | 12.3 ± 2.2 | 12.8 ± 2.1 | 11.5 ± 1.8 | 12.5 ± 2.0 | 11.6 ± 2.7 | <0.001 |
| Hematocrit (%) | 36.6 ± 6.2 | 37.7 ± 6.1 | 34.7 ± 5.5 | 37.0 ± 5.9 | 35.3 ± 8.0 | 0.010 |
| CRP (mg/dL) | 15.2 ± 11.3 | 13.1 ± 10.3 | 14.4 ± 11.8 | 16.9 ± 11.1 | 16.7 ± 13.1 | 0.054 |
| Creatinine (mg/dL) | 2.1 ± 1.8 | 1.7 ± 1.7 | 2.4 ± 2.1 | 2.0 ± 1.5 | 2.6 ± 2.2 | 0.026 |
| eGFR (mL/min/1.73 m2) | 54.0 ± 27.7 | 59.0 ± 26.5 | 56.9 ± 29.9 | 49.5 ± 26.5 | 49.5 ± 29.5 | 0.045 |
| Albumin (g/dL) | 3.3 ± 0.7 | 3.6 ± 0.6 | 2.9 ± 0.8 | 3.4 ± 0.6 | 2.9 ± 0.8 | <0.001 |
| Total cholesterol (mg/dL) | 128.7 ± 43.0 | 138.3 ± 41.9 | 115.1 ± 44.1 | 131.4 ± 39.8 | 114.8 ± 46.3 | 0.001 |
| Total bilirubin (mg/dL) | 1.3 ± 1.5 | 1.2 ± 1.1 | 1.3 ± 1.7 | 1.2 ± 1.1 | 1.7 ± 2.7 | 0.224 |
| pH | 7.42 ± 0.10 | 7.43 ± 0.08 | 7.41 ± 0.12 | 7.43 ± 0.09 | 7.39 ± 0.09 | 0.113 |
| Bicarbonate (mEq/L) | 21.0 ± 5.2 | 21.1 ± 4.9 | 20.8 ± 5.6 | 21.3 ± 5.1 | 20.6 ± 6.1 | 0.094 |
| Lactate (mmol/L) | 3.40 ± 2.80 | 3.17 ± 2.64 | 3.77 ± 2.56 | 3.13 ± 2.93 | 4.35 ± 3.00 | 0.065 |
| 0.002 | ||||||
| Lung (pneumonia) | 80 (24.3%) | 15 (13.9%) | 23 (36.5%) | 24 (19.8%) | 18 (48.6%) | |
| Urinary tract | 81 (24.6%) | 30 (27.8%) | 10 (15.9%) | 37 (30.6%) | 4 (10.8%) | |
| Intra-abdominal site | 72 (21.9%) | 29 (26.9%) | 10 (15.9%) | 26 (21.5%) | 7 (18.9%) | |
| Other | 71 (21.6%) | 28 (25.9%) | 14 (22.2%) | 24 (19.8%) | 5 (13.5%) | |
| Multiple sites | 25 (7.6%) | 6 (5.6%) | 6 (9.5%) | 10 (8.3%) | 3 (8.1%) | |
| 174 (52.9%) | 49 (45.4%) | 35 (55.6%) | 68 (56.2%) | 22 (59.5%) | 0.284 | |
| 54 (16.4%) | 6 (5.6%) | 15 (23.8%) | 16 (13.2%) | 17 (45.9%) | <0.001 | |
| 33 (10.0%) | 2 (1.9%) | 11 (17.5%) | 8 (6.6%) | 12 (32.4%) | <0.001 | |
| 48 (14.6%) | 2 (1.9%) | 13 (20.6%) | 16 (13.2%) | 17 (45.9%) | <0.001 | |
| 19.3 ± 22.8 | 14.3 ± 11.7 | 26.9 ± 22.8 | 16.6 ± 10.8 | 44.2 ± 64.3 | <0.001 | |
Data are expressed as mean (with SD) or n (%). †Group 1 was defined as patients with RDW levels with the reference range (normal RDW level) at baseline and ΔRDW72hr-adm ≤0.2%, group 2 as patients with increased RDW at baseline and ΔRDW72hr-adm ≤0.2%, group 3 as patients with normal RDW at baseline and ΔRDW72hr-adm >0.2%, and group 4 as patients with increased RDW at baseline and ΔRDW72hr-adm >0.2%; ‡acute kidney injury was defined as any of the following: (i) increase in serum creatinine by ≥0.3 mg/dL within 48 hours, (ii) increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, (iii) urine volume <0.5 ml/kg/hour for 6 hours. RDW, red blood cell distribution width; ΔRDW72hr-adm, RDW at 72 hours – RDW at baseline; MAP, mean arterial pressure; BMI, body mass index; WBC, white blood cell; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy.
Figure 2Kaplan-Meier plots for cumulative 28-day (A) and 90-day (B) survival according to baseline red blood cell distribution width (RDW) value and ΔRDW(ΔRDW, RDW at 72 hours – RDW at baseline). Group 1 included patients with RDW levels in the reference range (normal RDW level) at baseline and ΔRDW72hr-adm ≤0.2%, group 2 comprised patients with increased RDW at baseline and ΔRDW72hr-adm ≤0.2%, group 3 included patients with normal RDW at baseline and ΔRDW72hr-adm >0.2%, and group 4 was made up of patients with increased RDW at baseline and ΔRDW72hr-adm >0.2% (P <0.001 by log-rank test for overall comparison among groups in both 28-day and 90-day cumulative survival plots).
Cox proportional hazards analyses for 28-day and 90-day mortality according to baseline RDW value and ΔRDW
| Group 1 | 1.0 | - | 1.0 | - | 1.0 | - |
| Group 2 | 10.09 (2.24 to 45.52) | 0.003 | 4.57 (0.93 to 22.47) | 0.062 | 4.86 (0.93 to 25.29) | 0.060 |
| Group 3 | 3.64 (0.77 to 17.14) | 0.102 | 1.31 (0.26 to 6.49) | 0.743 | 1.72 (0.34 to 8.69) | 0.513 |
| Group 4 | 21.78 (4.85 to 96.95) | <0.001 | 7.85 (1.63 to 37.76) | 0.010 | 9.97 (1.99 to 49.91) | 0.005 |
| Group 1 | 1.0 | - | 1.0 | - | 1.0 | - |
| Group 2 | 12.41 (2.80 to 54.98) | 0.001 | 4.93 (1.06 to 22.94) | 0.042 | 4.72 (1.00 to 22.27) | 0.050 |
| Group 3 | 7.44 (1.71 to 32.34) | 0.007 | 3.85 (0.87 to 17.04) | 0.076 | 4.78 (1.07 to 21.31) | 0.040 |
| Group 4 | 33.41 (7.71 to 144.70) | <0.001 | 11.66 (2.57 to 52.97) | 0.001 | 13.74 (2.95 to 64.10) | 0.001 |
Unadjusted Model: crude relative risk. Adjusted Model 1: adjusted for age, sex, SOFA score, Charlson Comorbidity Index, renal replacement therapy, albumin, hemoglobin, lactate, and C-reactive protein. Adjusted Model 2: Model 1 plus adjustment for infection site. RDW, red cell distribution width.
Independent predictors of total length of hospital stay (TLHS) by multivariate linear regression analysis
| Group 1 | 1.0 | - | - |
| Group 2 | 8.33 | 0.04 to 16.62 | 0.049 |
| Group 3 | 0.72 | −5.24 to 6.67 | 0.813 |
| Group 4 | 25.45 | 14.69 to 36.21 | <0.001 |
| Urinary tract | 1.0 | - | - |
| Intra-abdominal site | 1.42 | −6.01 to 8.86 | 0.707 |
| Other | −0.10 | −7.91 to 7.72 | 0.981 |
| Lung (pneumonia) | 14.98 | 6.81 to 23.15 | <0.001 |
| Multiple sites | 9.43 | −3.08 to 21.95 | 0.139 |
| −0.06 | −0.23 to 0.107 | 0.462 | |
| −1.14 | −7.07 to 4.79 | 0.706 | |
| 1.01 | −0.19 to 2.21 | 0.099 | |
| 0.08 | −1.93 to 2.09 | 0.937 | |
| 2.44 | −7.19 to 12.07 | 0.618 | |
| −2.65 | −7.32 to 2.03 | 0.266 | |
| 0.75 | −0.65 to 2.14 | 0.292 | |
| −0.16 | −1.33 to 1.00 | 0.782 | |
| 0.01 | −0.02 to 0.03 | 0.504 | |
RDW, red blood cell distribution width; RRT, renal placement therapy; CRP, C-reactive protein.